Molnupiravir

‌Molnupiravir | CAS 2349386-89-4 | USP/EP-Certified Antiviral API for COVID-19 Treatment‌
‌Google Keywords‌: Molnupiravir bulk supplier, antiviral API for COVID-19, USP/EP-certified Molnupiravir, RNA mutagen drug

🌟 ‌Product Overview‌

Molnupiravir (CAS 2349386-89-4) is an oral antiviral nucleoside analog designed to treat mild-to-moderate COVID-19 by inducing RNA mutagenesis during viral replication, effectively reducing viral load and transmission risk. As a broad-spectrum antiviral agent, it is formulated as a white crystalline powder for clinical use and research applications.

✔️ ‌Key Advantages‌

• ‌High Purity‌: ≥99% HPLC purity compliant with ‌USP/EP standards‌, ensuring pharmaceutical-grade quality.

• ‌Bulk Customization‌: Available in ‌1kg–25kg batches‌ with batch-specific COA, MSDS, and stability data.

• ‌Solubility‌: Optimized for DMSO solubility (≥20 mg/mL) to support preclinical and clinical studies.

🏥 ‌Applications‌

• ‌COVID-19 Therapy‌: First-line oral treatment to reduce symptom severity and hospitalization rates.

• ‌Antiviral Drug Development‌: Key reference standard for RNA virus-targeted drug discovery.

• ‌Research‌: Mechanistic studies on viral mutagenesis and resistance profiling.

📜 ‌Quality Compliance‌

• Certified under ‌USP/EP guidelines‌ with heavy metals <20 ppm and residual solvents <10 ppm.

• Stability tested for ‌24 months‌ when stored at -20°C in airtight, light-protected packaging.

📈 ‌Market Trends‌

The global antiviral drug market is projected to grow at ‌7.8% CAGR (2025-2030)‌, driven by ongoing demand for COVID-19 therapeutics. Molnupiravir’s oral bioavailability and rapid action position it as a critical tool in pandemic preparedness.